

Reference List

- (1) Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (Clinical Guideline CG67). NICE Guideline 2010 Mar.
- (2) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;251:351-64.
- (3) Langlois MR, Blaton VH. Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. *Clinica Chimica Acta* 2006;369:168-78.
- (4) Warnick GR, Nauck M, Rifai N. Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays. *Clinical Chemistry* 2001;47(9):1579-96.
- (5) Diabetes UK. Diabetes in the UK 2010: Key statistics on diabetes. 2010.
Ref Type: Generic
- (6) Robinson S, Harris H. A Report on the 2009 General Lifestyle Survey (Office for National Statistics). 2011.
Ref Type: Generic
- (7) Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. *American Heart Journal* 1991;121(1 Pt 2):293-8.
- (8) Welcome to the QRISK®2-2011 risk calculator: <http://qrisk.org>. 2011. 1-5-2011.
Ref Type: Internet Communication
- (9) Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. *Lancet* 1996;348(9024):387-8.
- (10) Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. *Lancet* 1995;346:1467-71.
- (11) Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ* 2007;335(7611):136.